# Combination of Rituximab and NK Immunotherapy for B Lymphoma

> **NCT02843061** · PHASE1,PHASE2 · COMPLETED · sponsor: **Fuda Cancer Hospital, Guangzhou** · enrollment: 30 (actual)

## Conditions studied

- B-cell Lymphoma Recurrent

## Interventions

- **DRUG:** Rituximab
- **BIOLOGICAL:** NK immunotherapy

## Key facts

- **NCT ID:** NCT02843061
- **Lead sponsor:** Fuda Cancer Hospital, Guangzhou
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-01
- **Primary completion:** 2017-07-01
- **Final completion:** 2019-07-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2019-09-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02843061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02843061, "Combination of Rituximab and NK Immunotherapy for B Lymphoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02843061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*